Background: The role of chemotherapy dose-intensification in small-cell lung cancer (SCLC) remains unclear. This phase I-II study evaluates feasibility and outcome of combination chemotherapy at moderately elevated doses with concomitant thoracic radiotherapy in limited-disease SCLC.

Patients And Methods: Moderately elevated doses of ifosfamide-epirubicin (cycles 1 and 3) and of carboplatin-etoposide (cycles 2 and 4) were given with G-CSF and peripheral blood stem-cell (PBSC) support. Thoracic radiotherapy (40 Gy) was given once daily during the first five days of each cycle.

Results: Overall toxicity was acceptable; most common side-effects were myelosuppression and asthenia. All 35 eligible patients responded (23 CR, 12 PR). Median time to progression was 15 months: median overall survival was 24.6 months. Only 6 of 25 relapsing patients (24%) presented with a locoregional recurrence while 12 of 25 (48%) relapsed in the central nervous system (CNS).

Conclusions: This regimen is a feasible dose-intensification with an acceptable toxicity profile. Its efficacy was demonstrated by a 100% response rate, an excellent local tumor control rate and a median survival of 24.6 months. In the absence of PCI, CNS relapse is a major problem if adequate local control is achieved.

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1008306732232DOI Listing

Publication Analysis

Top Keywords

thoracic radiotherapy
12
combination chemotherapy
8
concomitant thoracic
8
radiotherapy limited-disease
8
small-cell lung
8
lung cancer
8
tumor control
8
central nervous
8
nervous system
8
moderately elevated
8

Similar Publications

Background: Trunk reconstruction following sarcoma excision involves significant defects. Pedicled and free latissimus dorsi myocutaneous flap (LDMF) reconstruction is commonly employed for thoracic defects; however, skin paddle design is limited to 10-12 cm to achieve primary donor closure. Paucity of data exists regarding the utility of V-Y advancement of LDMF, previously described for moderately sized thoracic defects.

View Article and Find Full Text PDF

Objectives: The pairing of immunotherapy and radiotherapy in the treatment of locally advanced nonsmall cell lung cancer (NSCLC) has shown promise. By combining radiotherapy with immunotherapy, the synergistic effects of these modalities not only bolster antitumor efficacy but also exacerbate lung injury. Consequently, developing a model capable of accurately predicting radiotherapy- and immunotherapy-related pneumonitis in lung cancer patients is a pressing need.

View Article and Find Full Text PDF

Primary tracheo-bronchial adenoid cystic carcinoma: A surgical series with literature review.

Respirol Case Rep

January 2025

Thoracic Surgery Department Abderrahmen Mami University Hospital-Ariana, Faculty of Medicine of Tunis, University of Tunis El Manar Ariana Tunisia.

Tracheo-bronchial adenoid cystic carcinoma (TBACC) is a rare disease. Its treatment is mainly surgical. We herein describe the clinical and para-clinical varieties of TBACC as well as their surgical treatment and prognosis.

View Article and Find Full Text PDF

Aim: The lungs represent the second most common site of colorectal cancer metastases. Although surgery is commonly considered the best treatment, many other invasive and noninvasive procedures and treatments have been adopted to improve patient survival and there is no clear evidence in the literature of which is the more effective. The aim of this work was to identify which treatment confers the best gain in overall survival for patients with pulmonary metastases from colorectal cancer.

View Article and Find Full Text PDF

Background: No study has directly compared the outcomes of surgery and concurrent chemoradiotherapy (cCRT) in patients with stage III non-small cell lung cancer (NSCLC) to date. This study aimed to compare the treatment efficacy of complete resection and definitive cCRT.

Methods: Patients were recruited in this retrospective study from Yokohama Municipal Citizens' Hospital between January 2013 and December 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!